BioVaxys Technology Corp, a Canadian biotechnology company, has been making strides in the development of vaccines and immunotherapy products. Headquartered in Vancouver, British Columbia, the company was incorporated in 2001 and has since been a significant player in life sciences research and development. BioVaxys is dedicated to addressing global health challenges, with a particular focus on infectious diseases and cancer.
The company’s mission is to revolutionize the treatment and prevention of infectious diseases and to pioneer new immunotherapy approaches for cancer. One of its flagship products is VaxMite, a novel vaccine under development aimed at protecting against Plasmodium falciparum, the most lethal form of malaria. This innovative vaccine represents a critical step forward in the fight against malaria, a disease that continues to have a devastating impact on global health.
In addition to VaxMite, BioVaxys is exploring the potential applications of its technology platform across various medical and healthcare domains. The company’s commitment to innovation is evident in its ongoing research and development efforts, which are geared towards creating transformative solutions for pressing health issues.
Financially, BioVaxys Technology Corp is listed on the Canadian National Stock Exchange, with its shares priced at CAD 0.26 as of November 13, 2025. The company’s market capitalization stands at CAD 7,630,000. Over the past year, the stock has experienced fluctuations, reaching a 52-week high of CAD 0.7 on January 2, 2025, and a low of CAD 0.17 on October 19, 2025. The price-to-earnings ratio is currently -1.2, reflecting the company’s ongoing investment in research and development, which may not yet be reflected in earnings.
BioVaxys Technology Corp continues to focus on its core mission of developing innovative healthcare solutions, with the potential to make significant contributions to global health through its cutting-edge research and development initiatives.